FDA approves Roche’s VENTANA ALK (D5F3) CDx Assay for use on the VENTANA BenchMark ULTRA system

Roche (SIX: RO, ROG; OTCQX:RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved the VENTANA ALK (D5F3) CDx Assay1 for use on the VENTANA BenchMark ULTRA automated slide stainer. The assay is a companion diagnostic to aid in the identification of ALK-positive lung cancer patients who are eligible for treatment with Pfizer’s FDA-approved therapy XALKORI®(crizotinib).Continue reading

Preventing Heart Disease Among Hispanic Diabetes Patients in Arizona, Focus of UA Research

 

Reducing cardiovascular disease and complications among Hispanic diabetes patients in Arizona is the focus of a new research project for Tomas Nuño, PhD, assistant professor of public health practice and translational research at the UA Mel and Enid Zuckerman College of Public Health – Phoenix and the Department of Emergency Medicine at the UA College of Medicine – TucsonContinue reading